Mechanisms in the skeletal complications of breast cancer

Endocrine-Related Cancer

Volumn 7, Issue 4, 2000, Pages 271-284

  Martin, T J ^a   Moseley, J M ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CYTOKINE; MATRIX METALLOPROTEINASE; PAMIDRONIC ACID; PARATHYROID HORMONE RELATED PROTEIN; PROSTAGLANDIN;

BONE METASTASIS; BREAST CANCER; CANCER MORTALITY; FEMALE; HUMAN; HUMAN CELL; HYPERCALCEMIA; LIVER METASTASIS; LUNG METASTASIS; PATHOLOGIC FRACTURE; REVIEW;

BONE NEOPLASMS; BREAST NEOPLASMS; CYTOKINES; FEMALE; HUMANS; HYPERCALCEMIA; MATRIX METALLOPROTEINASES; OSTEOCLASTS; PARATHYROID HORMONE-RELATED PROTEIN; PROSTAGLANDINS; PROTEINS;

EID: 0034473269     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.0.0070271     Document Type: Review

References (122)

1. Secretion of prostaglandins as bone-resorbing agents by renal cortical carcinoma in culture
2. Expression of bone sialoprotein, a bone matrix protein, in human breast cancer
3. Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development
4. Expression of bone sialoprotein in primary human breast cancer is associated with poor survival
5. Roles of the matrix metalloproteinases in mammary gland development and cancer
6. Prostaglandins and breast cancer
7. Breast cancer, prostaglandins and patient survival
8. Bisphosphonates in the treatment of malignant bone disease
9. Polymerase chain reaction analysis of parathyroid hormone-related protein gene expression in breast cancer patients and occurrence of bone metastases
10. Factors regulating the growth of metastatic cancer in bone
11. Anti integrin v3 blocks human breast cancer grown and angiogenesis
12. High levels of parathyroid hormone-like protein in milk
13. Parathyroid hormone related protein and skeletal morbidity in breast cancer
14. Identification of a novel 17 000-dalton parathyroid hormone-like adenylate cyclase-stimulating protein from a tumor associated with humoral hypercalcemia of malignancy
15. Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer
16. Oestrogen-receptor status and sites of metastasis in breast cancer
17. Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy
18. Osteoclasts are required for bone tumors to grow and destroy bone
19. Human breast cancer induces osteoclast activation and increases the number of osteoclasts at sites of tumor osteolysis
20. Review of cellular mechanisms of tumor osteolysis
21. The clinical course of bone metastases from breast cancer
22. Failure of indomethacin to reduce hypercalcemia in patients with breast cancer
23. Expression of transcripts of interleukin-6 and related cytokines by human breast tumors, breast cancer cells, and adipose stromal cells
24. Interleukin-6 enhances hypercalcemia and bone resorption mediated by parathyroid hormone-related protein in vivo
25. Expression and function of members of the cytokine receptor superfamily on breast cancer cells
26. Human breast tumour-induced osteolysis and prostaglandins
27. Benign breast lesions and osteolysis
28. Direct resorption of bone by human breast cancer cells in vitro
29. Structural requirements for the action of parathyroid hormone-related protein (PTHrP) on bone resorption by isolated osteoclasts
30. Influence of androgenic and estrogenic substances on serum calcium in cases of skeletal metastases from mammary cancer
31. Mechanisms of bone destruction in the development of skeletal metastases
32. Mechanisms of lytic and blastic metastatic disease of bone
33. Breast cancer-associated hypercalcaemia: A reassessment of renal calcium and phosphate handling
34. TGF-beta enhances osteoclast differentiation in hematopoietic cell cultures stimulated with RANKL and M-CSF
35. Vascular integrin alpha(v) beta3: A new prognostic indicator in breast cancer
36. SPARC/osteonectin induces matrix metalloproteinase 2 activation in human breast cancer cell lines
37. Calcitonin receptors, bone sialoprotein and osteopontin are expressed in primary breast cancers
38. Expression of osteonectin mRNA in human breast tumours is inversely correlated with oestrogen receptor content
39. Hypercalcaemia in carcinoma of the female breast
40. Prostaglandins as mediators of bone resorption in renal and breast tumours
41. Parathyroid hormone-related protein: Elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer
42. Parathyroid hormone-related protein: A possible endocrine function in lactation
43. Parathyroid hormone-related protein and bone metastases
44. Molecular mechanisms of osteolytic bone metastases
45. The combined effect of tumor-produced parathyroid hormone-related protein and transforming growth factor-alpha enhance hypercalcemia in vivo and bone resorption in vitro
46. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis
47. Serum calcium, inorganic phosphorus and phosphatase activity in hyperparathyroidism, Paget's disease, multiple myeloma and neoplastic diseases of bone
48. Role of organ selectivity in the determination of metastatic patterns of B16 melanoma
49. Parathyroid hormone-related protein in breast cancer: Improved patient survival and reduced bone metastases
50. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer
51. Similarity of synthetic peptide from human tumor to parathyroid hormone in vivo and in vitro
52. Osseous metastases of breast cancer. Clinical, biochemical, radiographic, and scintigraphic evaluation of response to therapy
53. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases
54. Long-term prevention of skeletal complications of metastatic breast carcinoma with pamidronate
55. Hypercalcemia in breast cancer. Reassessment of the mechanism
56. Letter: Indomethacin-responsive hypercalcemia
57. Expression of interleukin-6, interleukin-6 receptor, and glycoprotein 130 correlates with good prognoses for patients with breast carcinoma
58. Hypercalcaemia a complication of hormone therapy of advanced breast cancer
59. Hypercalcemia, a complication of hormone therapy of advanced breast cancer
60. Parathyroid hormone related protein in breast cancers of widely varying prognosis
61. Elevated nephrogenous cyclic AMP with normal serum parathyroid hormone levels in patients with lung cancer
62. Tumor resection and antibodies to parathyroid hormone-related protein cause similar changes on bone histomorphometry in hypercalcemia of cancer
63. PTHrP and cell division: Expression and localization of PTHrP in a keratinocyte cell line (HaCaT) during the cell cycle
64. Importin beta recognizes parathyroid hormone-related protein with high affinity and mediates its nuclear import in the absence of importin alpha
65. Phosphorylation at the cyclin-dependent kinases site (Thr85) of parathyroid hormone-related protein negatively regulates its nuclear localization
66. Production and regulation of interleukin-11 by breast cancer cells
67. A novel orthotopic model of breast cancer metastasis to bone
68. Integrin alpha V beta 3 expression by bone-residing breast cancer metastases
69. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: Long term follow-up of two randomized, placebo-controlled trials
70. Matrix metalloproteinases: Multifunctional contributors to tumor progression
71. Identification of a cDNA encoding a parathyroid hormone-like peptide from a human tumor associated with humoral hypercalcemia of malignancy
72. Biochemical regulators of bone resorption and their significance in cancer
73. Prostaglandins, cancer and bone: Pharmacological considerations
74. Parathyroid hormone-related protein: Hormone and cytokine
75. Interleukins in the control of osteoclast differentiation
76. Parathyroid hormone production and malignancy
77. Response of bone for tumor invasion
78. Parathyroid hormone-related protein purified from a human lung cancer cell line
79. Immunocytochemical demonstration of PTHrP protein in neoplastic tissue of HTLV-1 positive human adult T cell leukaemia/lymphoma: Implications for the mechanism of hypercalcaemia
80. The hypercalcemia of malignancy: Pathogenesis and management
81. Organ specificity of tumor metastasis: Role of preferential adhesion, invasion and growth of malignant cells at specific secondary sites
82. The distribution of secondary growths in cancer of the breast
83. Mechanism of malignant hypercalcaemia in carcinoma of the breast
84. Localization of parathyroid hormone-related protein in breast cancer metastases: Increased incidence in bone compared with other sites
85. The inhibition by aspirin and indomethacin of osteolytic tumor deposits and hypercalcaemia in rats with Walker tumour, and its possible application to human breast cancer
86. Breast-cancer osteolysis, bone metastases, and anti-osteolytic effect of aspirin
87. Comparison of the effects of amino-terminal synthetic parathyroid hormone-related peptide (PTHrP) of malignancy and parathyroid hormone on resorption of cultured fetal rat long bones
88. Relative contribution of humoral and metastatic factors to the pathogenesis of hypercalcaemia in malignancy
89. Parathyroid hormone-related protein and hypercalcemia
90. Production of parathyroid hormone-related protein by the mammary gland of the goat
91. Hypercalcaemia induced by prostaglandin E2 in thyroparathyroidectomized but not intact rats
92. Therapeutic approaches to bone diseases
93. Evidence for a novel parathyroid hormone-related protein in fetal lamb parathyroid glands and sheep placenta: Comparisons with a similar protein implicated in humoral hypercalcaemia of malignancy
94. Matrix metalloproteinase in remodelling of the normal and neoplastic mammary gland
95. Urinary and nephrogenous adenosine 3′5′-monophosphate in the hypercalcemia of malignancy
96. Bone metastases: Pathogenesis, treatment, and rationale for use of resorption inhibitors
97. Metastatic breast cancer confined to the skeletal system. An indolent disease
98. Immunohistochemical localization of parathyroid hormone-related protein in human breast cancer
99. Tamoxifen and life-threatening hypercalcaemia
100. Biochemical evaluation of patients with cancer-associated hypercalcemia: Evidence for humoral and nonhumoral groups
101. Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer
102. Synthetic human parathyroid hormone-like protein stimulates bone resorption and causes hypercalcaemia in rats
103. Oestrogen receptors, sites of metastatic disease and survival in recurrent breast cancer
104. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families
105. Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the alpha(v)beta3 and alpha(v)beta5 integrins
106. A parathyroid hormone-related protein implicated in malignant hypercalcemia: Cloning and expression
107. Evidence that the bone resorption-stimulating factor produced by mouse fibrosarcoma cells is prostaglandin E2. A new model for the hypercalcemia of cancer
108. Medical treatment of bone metastases
109. Expression of a calcium-mobilizing parathyroid hormone-like peptide in lactating mammary tissue
110. Breast cancer cells interact with osteoblasts to support osteoclast formation
111. Incidence, prevalence and distribution of bone metastases
112. Localization of parathyroid hormone-related protein mRNA expression in breast cancer and metastatic lesions by in situ hybridization
113. Hypercalcemia and tumor-prostaglandins: The VX2 carcinoma model in the rabbit
114. Overexpression of parathyroid hormone-related protein or parathyroid hormone in transgenic mice impairs branching morphogenesis during mammary gland development
115. Rescue of the parathyroid hormone-related protein knockout mouse demonstrates that parathyroid hormone-related protein is essential for mammary gland development
116. Concentrations of parathyroid hormone-related protein in rat milk change with duration of lactation and interval from previous suckling, but not with milk calcium
117. Prognostic significance of bone metastasis from breast cancer
118. Effects of a synthetic peptide of a parathyroid hormone-related protein on calcium homeostasis, renal tubular calcium reabsorption, and bone metabolism in vivo and in vitro in rodents
119. TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development
120. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2
121. Actions of bisphosphonates on bone metastasis in animal models of breast carcinoma